Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

Most patients with chronic pain continue to receive prescription opioids after nonfatal overdose

Most patients with chronic pain continue to receive prescription opioids after nonfatal overdose

A study led by Boston Medical Center indicates that most patients with chronic pain who are hospitalized after a nonfatal opioid overdose continue to receive prescription opioids after the overdose and are at high risk for experiencing a repeated overdose. [More]
Opioid prescribing guideline has immediate, sustained impact on prescribing rates

Opioid prescribing guideline has immediate, sustained impact on prescribing rates

Emergency medicine physicians at Temple University Hospital have found that an opioid prescribing guideline had an immediate and sustained impact on opioid prescribing rates for minor conditions and chronic noncancer pain in an acute care setting. [More]
Harmony Health Plan of Illinois to donate $10,000 to Kidz Korna

Harmony Health Plan of Illinois to donate $10,000 to Kidz Korna

Harmony Health Plan of Illinois, Inc., a subsidiary of WellCare Health Plans, Inc. (NYSE: WCG), will give $10,000 to Kidz Korna to help make the holidays special for 10,000 low-income children in Chicago's Englewood community. [More]
Young teens more vulnerable to opioid addiction, study reveals

Young teens more vulnerable to opioid addiction, study reveals

A Michigan State University study shows that 14- and 15-year-olds are at a higher risk of becoming dependent on prescription drugs within a 12-month period after using them extra-medically, or beyond the prescribed amount. [More]
New survey shows how patients, pharmacists benefit from med sync programs

New survey shows how patients, pharmacists benefit from med sync programs

A recent survey of National Community Pharmacists Association member pharmacies utilizing NCPA's Simplify My Meds (SMM) program documented how both patients and pharmacists benefit from medication synchronization programs, or "med sync." [More]
HealthCare Partners Medical Group receives IHA Medicare Advantage 4.5 Star Award

HealthCare Partners Medical Group receives IHA Medicare Advantage 4.5 Star Award

DaVita HealthCare Partners, a leading independent medical group in America and leading provider of kidney care services, today announced that HealthCare Partners Medical Group has received the Integrated Healthcare Association's Medicare Advantage 4.5 Star Award. [More]
New data shows opioid overdose deaths hit record levels in 2014

New data shows opioid overdose deaths hit record levels in 2014

From 2000 to 2014 nearly half a million Americans died from drug overdoses. Opioid overdose deaths, including both opioid pain relievers and heroin, hit record levels in 2014, with an alarming 14 percent increase in just one year, according to new data published today in CDC's Morbidity and Mortality Weekly Report. [More]
Variant signs worldwide exclusive license and development agreement with L&F Research

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200. [More]
Stanford study finds that overprescription of opioids goes beyond ‘pill mill’ prescribers

Stanford study finds that overprescription of opioids goes beyond ‘pill mill’ prescribers

Most prescriptions for opioid painkillers are made by the broad swath of U.S. general practitioners, not by a limited group of specialists, according to a study by researchers at the Stanford University School of Medicine. [More]
FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection. [More]
New guidelines may help reduce medication use among seniors

New guidelines may help reduce medication use among seniors

We're not getting any younger. According to the Administration for Community Living, by 2060, there will be about 98 million older persons in the United States — more than twice their number in 2013. [More]
Economic and racial barriers impact treatment of moderate to severe psoriasis

Economic and racial barriers impact treatment of moderate to severe psoriasis

In the first known study to examine the prevalence and treatment of psoriasis in older Americans, experts from the Perelman School of Medicine at the University of Pennsylvania have found that black patients receiving Medicare are less likely to receive biologic therapies -medications derived from human or animal cells or tissues - for the treatment of moderate to severe psoriasis than white patients. [More]

Meridian Health Plan wins 2015 Top Workplaces award

Meridian Health Plan has been awarded a 2015 Top Workplaces honor by the Detroit Free Press. The Top Workplaces lists are based solely on the results of an employee feedback survey administered by WorkplaceDynamics, LLC, a leading research firm that specializes in organizational health and workplace improvement. [More]
Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Health experts at Johns Hopkins Medicine are calling on lawmakers and regulators to close loopholes in the Orphan Drug Act they claim give drug companies millions of dollars in unintended and misplaced subsidies and tax breaks and fuel skyrocketing medication costs. [More]
Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage. [More]
FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin. [More]
Experts issue recommendations aimed at stemming prescription opioid epidemic

Experts issue recommendations aimed at stemming prescription opioid epidemic

A group of experts, led by researchers at the Johns Hopkins Bloomberg School of Public Health, today issued recommendations aimed at stemming the prescription opioid epidemic, a crisis that kills an average of 44 people a day in the U.S. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]

SKYGEN USA announces launch of Hylis Pharmacy Solutions

Citing a need to bring skyrocketing pharmacy costs under control, SKYGEN USA, the umbrella brand for a distinguished family of benefit management companies and technology solutions for health payers and healthcare organizations, today announced the launch of Hylis Pharmacy Solutions. [More]
Common heart drug may halt progression of angiosarcoma

Common heart drug may halt progression of angiosarcoma

A common heart drug may stop the progression of angiosarcoma, a cancer of the inner lining of blood vessels, according to a study by researchers at Texas Tech University Health Sciences Center El Paso. [More]
Advertisement